Skip to content

Effect of herbal medicine on digestive disorder

A Non-randomized, Single-Arm, Open-Label Pilot Study to Evaluate the Efficacy and Safety of MOLEQURE- Gastrointestinal Health in Adults with Functional Gastrointestinal Disorder - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/08/093264
Enrollment
24
Registered
2025-08-19
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K319- Disease of stomach and duodenum, unspecified

Interventions

None listed

Sponsors

AMBITN LIFESCIENCES
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult male and female subjects aged above 18 years with clinical diagnosis of Functional Gastrointestinal Disorder (FGID). 2. Subjects with mild to moderate gastrointestinal clinical symptoms, based on a GSRS. 3. Subjects with stable dietary and lifestyle patterns for the last 4 weeks 4. Willingness to comply with study procedures and provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Use of antibiotics, probiotics, prebiotics, or GI-targeting supplements in past 4 weeks 2. Subjects with organic GI diseases (IBD, celiac disease, peptic ulcer disease, GI malignancy) 3. History of gastrointestinal surgery within the past year 4. Severe psychiatric illness or any systemic disease deemed unsafe by the investigator 5. Pregnant or lactating women, or women planning to become pregnant during the study period. 6. Known allergy or hypersensitivity to any component of the investigational product 7. Use of any medications, supplements, or herbal products specifically intended for the treatment or management of liver disorders within the last 30 days. 8. Participation in any other clinical trial within 30 days prior to the screening visit.

Design outcomes

Primary

MeasureTime frame
Mean change in composite GI symptom score using a GSRS from baseline to different study visits.Timepoint: 28 days.

Secondary

MeasureTime frame
1) Mean change in the Gastrointestinal Quality of Life Index (GI-QoLI) from baseline to end of the study.Timepoint: 28 days.

Countries

India

Contacts

Public ContactManik Chaudhuri

J. B. Roy State Ayurvedic Medical College and Hospital

srikantapandit@gmail.com09831723650

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026